** 药物开发商Neoleukin Therapeutics 股价下跌12.4%至0.81美元。
** 私营基因药物公司Neurogene Inc和NLTX表示， (link)，他们已达成最终合并协议，将以全股票交易的方式合并两家公司。
** 合并完成后，合并后的公司将以Neurogene Inc的名称运营，并在纳斯达克交易，股票代码为 "NGNE"-NLTX。
** 合并后的公司将专注于开发Neurogene公司针对罕见发育障碍Rett综合征的实验性基因疗法 - NLTX
** 合并预计在2023年第四季度完成
** 包括盘中走势在内，NLTX股价今年累计上涨约68%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.